Andere talen Evoke Pharma, Inc.

Aandelen

EVOK

US30049G2030

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 05-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,54 ^USD	+0,88%		+2,08%	-48,59%

14/05	Evoke Pharma, Inc. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
14/05	Evoke Pharma, Inc. Herhaalt de omzetverwachtingen voor 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Evoke Pharma Reports Commercial Strategy Progress and Positive Momentum for GIMOTI	18/06
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI	17/06
Evoke Pharma, Inc. Appoints Mark A. Kowieski as Chief Financial Officer	28/05
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference	16/05
Evoke Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Evoke Pharma Reports First Quarter 2024 Financial Results	14/05
Evoke Pharma, Inc. Reiterates Revenue Guidance for 2024	14/05
Certain Options of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	09/05
Certain Common Stock of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	09/05
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications	17/04
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	21/03
Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	21/03
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	21/03
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	14/03
Evoke Pharma, Inc. Provides Earnings Guidance for 2024	14/03
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	07/03
Evoke Pharma Announces Closing of $7.5 Million Public Offering	14/02
Evoke Pharma Prices Underwritten Public Offering	09/02
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	09/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Evoke Pharma, Inc.

Aandelen

EVOK

US30049G2030

Andere talen

Filters